Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...

Novo Nordisk (NVO) is now offering its GLP-1 weight-loss drug Wegovy at half its price, amounting to $499 per month.

Insurance coverage for GLP-1 drugs remains tight despite rising demand, with more patients facing restrictions or paying out ...

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

In recent years, the growing list of medical benefits for GIP and GLP-1 agonists (think Ozempic for diabetes or Zepbound for ...

Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...

CagriSema from Novo Nordisk activates both GLP-1 and amylin receptors. It is currently the subject of several clinical trials ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

Glp-1s cover a variety of drugs that are commonly used for weight loss, such as Ozempic, Wegovy and Mounjaro. And West Virginians used them at the highest rate ...

Use of GLP-1 receptor agonists for obesity was associated with a reduced risk of primary open-angle glaucoma (POAG) and ...

Weight-loss drugs are changing the way people grocery shop and eat. But those spending habits don't necessarily last.

Patients using GLP-1 drugs had no difference in the odds of postoperative aspiration pneumonia versus non-users. Preoperative ...